Skip to content

Serotonin research published in 2018

Page 2 of 4: studies 21 to 40 of 73, newest first. Back to the serotonin overview

Studies

Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD.

Current Biology September 27, 2018 Gustavo Deco, Josephine Cruzat, Joana Cabral et al. 246 citations

Understanding the underlying mechanisms of the human brain in health and disease will require models with necessary and sufficient details to explain how function emerges from the underlying anatomy and is shaped by neuromodulation. Here, we provide such a detailed causal explanation using a whole-brain model integrating multimodal imaging in healthy human participants undergoing manipulation...

DOI: 10.1016/j.cub.2018.07.083 (opens in new tab) LSD Brain Effects Serotonin receptors Neuropharmacology

Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: high potency agonists at 5-HT2A receptors

Biochemical Pharmacology September 25, 2018 Amy J. Eshleman, Katherine M. Wolfrum, John F. Reed et al.

&NA; The use of new psychoactive substituted 2,5‐dimethoxy‐N‐benzylphenethylamines is associated with abuse and toxicity in the United States and elsewhere and their pharmacology is not well known. This study compares the mechanisms of action of 2‐(2,5‐dimethoxy‐4‐methylphenyl)‐N‐(2‐methoxybenzyl)ethanamine (25D‐NBOMe), 2‐(4‐ethyl‐2,5‐dimethoxyphenyl)‐N‐(2‐methoxybenzyl)ethanamine (25E‐NBOMe),...

Serotonin, psychedelics and psychiatry

World Psychiatry September 7, 2018 Robin Carhart-Harris 49 citations

Serotonin is a key neuromodulator known to be involved in brain development, perception, cognition, and mood. However, unlike as with dopamine for example, a compelling unified theory of brain serotonin function has not yet been established. This is likely due to the exceptional complexity of the serotonin system, with its 14+ receptors, over twice the number identified for any of the other...

DOI: 10.1002/wps.20555 (opens in new tab) Serotonin Neuropsychopharmacology Mood Psychoanalysis

Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews

Expert Review of Clinical Pharmacology August 13, 2018 Rafael G. Dos Santos, José Carlos Bouso, Miguel Ángel Alcázar‐córcoles et al. 231 citations

Mood, anxiety, and substance-use disorders are among the most prevalent psychiatric disorders in the population. Although several pharmacological treatments are available, they are not effective for a significant proportion of patients and are associated with several adverse reactions. Therefore, new treatments should be explored. Recent studies suggest that serotonergic...

Gene expression analysis indicates reduced memory and cognitive functions in the hippocampus and increase in synaptic reorganization in the frontal cortex 3 weeks after MDMA administration in Dark Agouti rats.

BMC Genomics August 2, 2018 Peter Petschner, Viola Tamasi, Csaba Ádori et al.

3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") is a widely used entactogenic drug known to impair cognitive functions on the long-run. Both hippocampal and frontal cortical regions have well established roles in behavior, memory formation and other cognitive tasks and damage of these regions is associated with altered behavior and cognitive functions frequently described in otherwise...

Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain

Translational Psychiatry July 16, 2018 Kai‐Chun Yang, Akihiro Takano, Christer Halldin et al. 17 citations

Abstract The serotonin (5-HT) system plays an important role in the pathophysiology and treatment of several major psychiatric disorders. Currently, no suitable positron emission tomography (PET) imaging paradigm is available to assess 5-HT release in the living human brain. [11C]AZ10419369 binds to 5-HT1Breceptors and is one of the most 5-HT-sensitive radioligands available. This study applied...

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

International Review of Psychiatry July 4, 2018 Albert Garcia‐romeu, William A. Richards 186 citations

Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20th century, considerable advances were made in developing therapeutic...

Psychedelics as anti-inflammatory agents

International Review of Psychiatry July 4, 2018 Thomas W. Flanagan, Charles D. Nichols 263 citations

Serotonin (5-hydroxytryptamine, 5-HT)2A receptor agonists have recently emerged as promising new treatment options for a variety of disorders. The recent success of these agonists, also known as psychedelics, like psilocybin for the treatment of anxiety, depression, obsessive-compulsive disorder (OCD), and addiction, has ushered in a renaissance in the way these compounds are perceived in the...

A genetic reduction in the serotonin transporter differentially influences MDMA and heroin induced behaviours.

Psychopharmacology July 2018 Bridget W Brox, Bart A. Ellenbroek

Despite ongoing study and research to better understand drug addiction, it continues to be a heavy burden. Only a small percentage of individuals who take drugs of abuse go on to develop addiction. However, there is growing evidence to suggest that a reduction in the serotonin transporter may play an important role for those that transition to compulsive drug taking. Studies have demonstrated...

Successful treatment of intractable visual hallucinations with 5-HT 2A antagonist ketanserin.

BMJ Case Reports June 27, 2018 Iris E C Sommer, Hidde Kleijer, Lucy Visser et al.

Hallucinations, visual, auditory or in another sensory modality, often respond well to treatment in patients with schizophrenia. Some, however, do not and can be very chronic and debilitating. We present a patient with schizophrenia with intractable hallucinations despite state of the art care, including high-dose clozapine and transcranial magnetic stimulation. Based on the possible role of...

DOI: 10.1136/bcr-2018-224340 (opens in new tab) Full text (opens in new tab) Humans Hallucinations Ketanserin Serotonin antagonists +6

Human Metabolome Changes after a Single Dose of 3,4-Methylenedioxymethamphetamine (MDMA) with Special Focus on Steroid Metabolism and Inflammation Processes

Journal of Proteome Research June 27, 2018 Martina I. Boxler, Gabriel L. Streun, Matthias E. Liechti et al. 23 citations

The intake of 3,4-methylenedioxymethamphetamine (MDMA) is known to increase several endogenous substances involved in steroid and inflammation pathways. Untargeted metabolomics screening approaches can determine biochemical changes after drug exposure and can reveal new pathways, which might be involved in the pharmacology and toxicology of a drug of abuse. We analyzed plasma samples from a...

The psychostimulant (±)-cis-4,4′-dimethylaminorex (4,4′-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters

Neuropharmacology June 23, 2018 Julian Maier, Felix P. Mayer, Dino Luethi et al. 24 citations

(±)-cis-4,4′-Dimethylaminorex (4,4′-DMAR) is a new psychoactive substance (NPS) that has been associated with 31 fatalities and other adverse events in Europe between June 2013 and February 2014. We used in vitro uptake inhibition and transporter release assays to determine the effects of 4,4′-DMAR on human high-affinity transporters for dopamine (DAT), norepinephrine (NET) and serotonin...

DOI: 10.1016/j.neuropharm.2018.06.018 (opens in new tab) Monoamine neurotransmitter Vesicular monoamine transporter Monoaminergic Pharmacology +7

Pre-clinical interaction of ayahuasca, a brew used in spiritual movements, with morphine and propofol

Brazilian Journal of Pharmaceutical Sciences June 7, 2018 Júlia Movilla Pires, Fúlvio Rieli Mendes, Ana Paula Salum Pires et al. 10 citations

ABSTRACT Ayahuasca is a beverage with psychoactive properties used in religious and ceremonial rituals by some religious groups. The main active components of ayahuasca are dimethyltryptamine and the harmala alkaloids with β-carboline structure acting as monoamine oxidase A inhibitors. This combination produces a pronounced activation of serotonergic pathways and presents potential interaction...

Psychedelics and Personality

ACS Chemical Neuroscience June 4, 2018 Marc Aixalà, Rafael G. Dos Santos, Jaime E. C. Hallak et al. 14 citations

In the past decade, an increasing number of clinical trials are reporting evidence that psychedelics or serotonergic hallucinogens (such as lysergic acid diethylamide, psilocybin, and ayahuasca/dimethyltryptamine) could be effective in the treatment of mood, anxiety, and substance use disorders. The mechanisms responsible for these effects are not fully understood but seem to involve changes in...

Positive regulation of raphe serotonin neurons by serotonin 2B receptors.

Neuropsychopharmacology June 2018 Arnauld Belmer, Emily Quentin, Silvina L Diaz et al.

Serotonin is a neurotransmitter involved in many psychiatric diseases. In humans, a lack of 5-HT2B receptors is associated with serotonin-dependent phenotypes, including impulsivity and suicidality. A lack of 5-HT2B receptors in mice eliminates the effects of molecules that directly target serotonergic neurons including amphetamine derivative serotonin releasers, and selective serotonin...

Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide

F1000Research May 24, 2018 Ronald S. Duman 203 citations

Therapeutic medications for the treatment of depression have serious limitations, particularly delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic dose of ketamine, a glutamate NMDA receptor channel blocker, can produce a rapid (within hours) antidepressant response that is sustained (about 1 week), even in patients considered treatment-resistant, has...

Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics

The International Journal of Neuropsychopharmacology May 24, 2018 Dino Luethi, Matthias E. Liechti

The rapid assessment of in vitro pharmacological profiles of new psychoactive substances can help to predict psychoactive doses and effects in humans and facilitate the appropriate scheduling of new psychoactive substances.

DOI: 10.1093/ijnp/pyy047 (opens in new tab) Full text (opens in new tab) Pharmacology Monoamine neurotransmitter Dopamine transporter Serotonin transporter +5

Classics in Neuroimaging: The Serotonergic 2A Receptor System—from Discovery to Modern Molecular Imaging

ACS Chemical Neuroscience May 15, 2018 Elina Tampio L’Estrade, Hanne Demant Hansen, Maria Erlandsson et al. 14 citations

High Resolution Image Download MS PowerPoint Slide Already in 1953, Woolley and Shaw speculated that serotonin could be involved in a range of central nervous system (CNS) disorders. Lysergic acid diethylamide (LSD) displayed an important role in this respect. It was used not only to antagonize biological effects of serotonin and to study the system itself, but also to identify serotonergic...